Article Text

Unexpected outcome (positive or negative) including adverse drug reactions
Acute hepatitis induced by glatiramer acetate
  1. Pierre Deltenre1,2,
  2. Marie-Odile Peny3,
  3. André Dufour4,
  4. Mohamed El Nady2,
  5. Jean Henrion1
  1. 1
    Hopital de Jolimont, Service d’Hépato-gastroentérologie, Rue Ferrer, 159, Haine-Saint-Paul, 7100, Belgium
  2. 2
    Hopital Huriez, Service d’Hépato-gastroentérologie, Avenue Oscar Lambret, Lille, 59037, France
  3. 3
    Hopital de Jolimont, Service d’anatomo-pathologie, Rue Ferrer, 159, Haine-Saint-Paul, 7100, Belgium
  4. 4
    General practitioner, Bois d’Haine, 7170, Belgium
  1. pierre.deltenre{at}


Glatiramer acetate, a mixture of synthetic polypeptides able to prevent autoimmune encephalomyelitis in experimental models, is used as a treatment for patients with active relapsing–remitting multiple sclerosis. We report one case of glatiramer acetate induced hepatitis. Liver biopsy was consistent with a diagnosis of drug induced hepatitis and alanine aminotransferase returned to normal values after treatment discontinuation. The present case should serve as a warning that glatiramer acetate may cause acute liver disease.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.

  • Patient consent: Patient/guardian consent was obtained for publication.